Insights

  • Date

  • Content Type

  • Reset

Blog

The regulatory environment for the development of mRNA vaccines during COVID-19

7.12.20

By Ciaran Greene

A growing interest in mRNA-based technologies over the last decades has allowed the rapid development and deployment of...

Read More

Blog

Vaccine Development in Paediatric Populations – How to Proceed for SARS-CoV-2 Vaccines?

5.11.20

By Jerry Fuady

While adult clinical trials of SARS-CoV-2 vaccines have rapidly moved into Phase 3, no clinical trials have been...

Read More

Blog

How far are we with the accelerated development of SARS-CoV-2 vaccines – a review and outlook

13.08.20

By Noemi Lupo and Michael Pfleiderer

Development of SARS-CoV-2 vaccine comes with an unprecedented number of challenges ranging from CMC to clinical development. This...

Read More

Blog

Accelerated development and licensure of Coronavirus vaccines

28.02.20

By Michael Pfleiderer

The newly emerging 2019 novel Coronavirus is threatening the world as it spreads with a so far unprecedented...

Read More

Blog

Platform technologies for vaccines – why is there still no regulatory guidance available?

3.09.19

By Michael Pfleiderer

The recent widespread, long-lasting and recurrent outbreaks of Ebolavirus, Chikungunyavirus, Denguevirus, Zikavirus once more prove the need...

Read More

Blog

EMA’s Article 58 procedure and WHO’s prequalification procedure – pathways to licensure worth to consider for vaccines and other medicinal products

18.04.19

By Michael Pfleiderer

There are challenges and opportunities for developers of vaccines and other medicinal products needed outside the EU...

Read More

We are now Cencora PharmaLex 

PharmaLex is now part of Cencora, a leading global healthcare company with a foundation in pharmaceutical distribution. In 2024 and beyond PharmaLex and all the companies in PharmaLex family will begin a journey to becoming Cencora as well. Cencora brings the companies and services together under one new name. The name will change, but the level of attention and service you receive remains the same.  

Know more